Portal de Periódicos da CAPES

Artigo Produção Nacional Revisado por pares

BIBTEX RIS

Cellular and humoral immune response in human Chagas’ disease after treatment with Benzonidazol

2016; American Association of Immunologists; Volume: 196; Issue: 1_Supplement Linguagem: Inglês

10.4049/jimmunol.196.supp.135.7

1550-6606

Virmondes Rodrigues, Mauricio Llaguno Llaguno, Dalmo Correia, Marcos Silva,

Synthesis and Biological Evaluation

Abstract Chagas’ disease (caused by Trypanosoma cruzi) remains a leading neglected tropical disease in the Americas, associated with 546,000 disability adjusted life years and 10,300 annual deaths. Even today there is a lack of studies proving the effectiveness and effects of treatment with benznidazole in chronic patients, as well as its effects on the cellular immune response. Therefore, we evaluate the clinical and immunological changes in chronic chagasic patients treated with benzonidazol after 48 months of therapy. We assessed the variation of anti T. cruzi IgG antibodies and their isotypes, before and after treatment and the production of cytokines and immunophenotypic profile of T lymphocytes after treatment with benzonidazol. We observed that the treatment did not alter the clinical outcome. In patients with cardiac form or with clinical deterioration was observed a decrease of IgG3 specific antibody and an increase in T. cruzi specific IgG1 antibodies. In patients with clinical deterioration, there was a decrease of Th2, Th17 and Treg cells in cultures stimulated with mitogens. We conclude that, in the chronic phase of Chagas’ disease, after 4 years of treatment, a higher number of Th17 and Treg cells are associated with no disease progression.